Search research articles
Contact Us
Filters
Showing results (81-90 of 150) with videos related to
Page
of 15
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 6, 2006
MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo
Teru Hideshima, Paola Neri, Pierfranchesco Tassone, et al.
Blood Cancer Journal
|
August 19, 2024
Dual therapeutic targeting of MYC and JUNB transcriptional programs for enhanced anti-myeloma activity
Judith Lind, Osman Aksoy, Michaela Prchal-Murphy, et al.
Experimental Hematology
|
July 24, 2002
beta-lapachone, a novel plant product, overcomes drug resistance in human multiple myeloma cells
Deepak Gupta, Klaus Podar, Yu Tzu Tai, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
December 14, 2006
The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma
Klaus Podar, Giovanni Tonon, Martin Sattler, et al.
Gastroenterology
|
November 8, 2006
Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity
Ellen Weisberg, Renee D Wright, Jingrui Jiang, et al.
British Journal of Haematology
|
September 20, 2011
The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications
Klaus Podar, Alexander Zimmerhackl, Mariateresa Fulciniti, et al.
Cancer Research
|
December 3, 2004
Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma
Laurence Catley, Yu-Tzu Tai, Reshma Shringarpure, et al.
Cancer Research
|
February 20, 2007
Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma
Klaus Podar, Marc S Raab, Giovanni Tonon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 3, 2005
Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma
Pierfrancesco Tassone, Paola Neri, Renate Burger, et al.
Journal for Immunotherapy of Cancer
|
May 3, 2024
Favorable impact of PD1/PD-L1 antagonists on bone remodeling: an exploratory prospective clinical study and ex vivo validation
Tamara Gassner, Christina Chittilappilly, Theo Pirich, et al.
Page
of 15
Search research articles
Search
Showing results (81-90 of 150) with videos related to
Sort By:
Page
of 15
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 6, 2006
MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo
Teru Hideshima, Paola Neri, Pierfranchesco Tassone, et al.
Blood Cancer Journal
|
August 19, 2024
Dual therapeutic targeting of MYC and JUNB transcriptional programs for enhanced anti-myeloma activity
Judith Lind, Osman Aksoy, Michaela Prchal-Murphy, et al.
Experimental Hematology
|
July 24, 2002
beta-lapachone, a novel plant product, overcomes drug resistance in human multiple myeloma cells
Deepak Gupta, Klaus Podar, Yu Tzu Tai, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
December 14, 2006
The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma
Klaus Podar, Giovanni Tonon, Martin Sattler, et al.
Gastroenterology
|
November 8, 2006
Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity
Ellen Weisberg, Renee D Wright, Jingrui Jiang, et al.
British Journal of Haematology
|
September 20, 2011
The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications
Klaus Podar, Alexander Zimmerhackl, Mariateresa Fulciniti, et al.
Cancer Research
|
December 3, 2004
Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma
Laurence Catley, Yu-Tzu Tai, Reshma Shringarpure, et al.
Cancer Research
|
February 20, 2007
Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma
Klaus Podar, Marc S Raab, Giovanni Tonon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 3, 2005
Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma
Pierfrancesco Tassone, Paola Neri, Renate Burger, et al.
Journal for Immunotherapy of Cancer
|
May 3, 2024
Favorable impact of PD1/PD-L1 antagonists on bone remodeling: an exploratory prospective clinical study and ex vivo validation
Tamara Gassner, Christina Chittilappilly, Theo Pirich, et al.
Page
of 15